Navigation Links
Tengion Provides Business Update and Reports First Quarter 2011 Financial Results
Date:5/12/2011

ng Statements Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to the Company's: (i) plans to develop and commercialize its product candidates, including the Neo-Urinary Conduit and the Neo-Kidney Augment; (ii) expectations regarding the initial clinical trial of the Neo-Urinary Conduit and (iii) expectations regarding planned preclinical studies of the Neo-Kidney Augment. Although Tengion believes that these statements are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there are a number of factors that may cause actual results to differ from these statements. For instance there can be no assurance that: (i) the Company's Neo-Urinary Conduit clinical trial will not be placed on clinical hold by the Food and Drug Administration, or FDA; (ii) patients enrolled in the Company's Neo-Urinary Conduit clinical trial will not experience additional adverse events, which could delay clinical trials or cause the Company to terminate the development of the Neo-Urinary Conduit; (iii) the Company will be able to successfully enroll patients in its clinical trials, including its initial clinical trial for the Neo-Urinary Conduit; (iv) the results of the clinical trial for the Neo-Urinary Conduit will support further development of that product candidate; (v) data from the Company's ongoing preclinical studies will continue to be supportive of advancing its preclinical product candidates; and (vi) the Company will be able to progress its product candidates that are undergoing preclinical testing, including the Neo-Kidney Augment, into clinical trial and (vii) the Company will be able to obtain the capital it needs to develop its product candidates and continue its operations.  For additional factors which could cause actual results to differ from expectations, reference is made to th
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
2. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
3. Tengion Announces Second Closing of Series C Financing
4. Tengion to Present at the Piper Jaffray 20th Annual Healthcare Conference
5. Tengion Presents New Data Supporting Key Urologic and Kidney Programs at 16th Annual Meeting of the International Society for Cellular Therapy
6. Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
7. Tengion Appoints A. Brian Davis Chief Financial Officer
8. Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010
9. Tengion Appoints Richard E. Kuntz, MD to its Board of Directors
10. Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference
11. Tengion to Present at the 13th Annual BIO CEO & Investor Conference and the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... BOULDER, Colo. , Jan. 23, 2015  Array BioPharma ... it has reached a definitive agreement with Novartis Pharma ... BRAF inhibitor currently in Phase 3 development.  This agreement is ... and GlaxoSmithKline PLC (GSK) on April 22, 2014, which are ...
(Date:1/22/2015)... Eckert & Ziegler Vitalea Science (EZVS), ... to the pharmaceutical and biotech industry, has announced that ... the position of Director of Science & Technology. , ... experience in drug metabolism and bioanalysis to EZVS in ...
(Date:1/22/2015)... , Jan. 22, 2015  Transwestern | RBJ today announces ... of office space for Shire a leading biopharmaceutical company, at ... Transwestern | RBJ,s Robert Richards , president, and ... lease for the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... Jan. 22, 2015  Transwestern | RBJ today announces the firm ... space for Shire a leading biopharmaceutical company, at Two Ledgemont ... RBJ,s Robert Richards , president, and Brian Cohen ... the entire five-floor building at 95 Hayden Ave. ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2
... SAN FRANCISCO, Jan. 14 Inverseon, Inc. ( http://www.inverseon.com ... from the United States Patent Office covering its oral ... clinical asthma study was published in the January 10, ... would be the first patent for the utilization of ...
... LOUIS, Jan. 14 At the Boston Atrial,Fibrillation ... will showcase three,advances in remote magnetic ablation that ... of its Niobe(R) Magnetic Navigation,System. In booth ... 3.0, with the QuikCAS(TM) Cardiodrive(R) System for enhanced ...
... Inspection LLC (L3I) has,successfully completed the Quality Management System ... for ISO 9001 and AS 9100,Certification under the rules ... 100% compliance and zero non-compliance issues. , ... of Operations, Scott McAfee led,the creation, organization and refinement ...
Cached Biology Technology:Inverseon's Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet 2Stereotaxis Showcases Advancements for Remote Magnetic Ablations 2Stereotaxis Showcases Advancements for Remote Magnetic Ablations 3Stereotaxis Showcases Advancements for Remote Magnetic Ablations 4Level 3 Inspection Achieves 100% Compliance in ISO 9001 & AS 9100 Certification 2
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
(Date:1/22/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a ... the recent success of the Wocket™ smart wallet at CES 2015 in ... was named as one of the "11 Hot Products at CES" in ... At CES So Far" by Newseveryday.com and "The top 10 gadgets from ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... The Journal of Experimental Medicine identifies a small genetic ... (TB). Pedro Flores-Villanueva and his colleagues at the ... of patients in Mexico and Korea and found that ... to develop disease when infected with TB-causing bacteria. , ...
... myriad insect forms—beetles, flies, dragonflies, mosquitoes, grasshoppers, ants, wasps, ... of all species known. The large number of insect ... one or more factors: a high rate of formation ... to new environments and exploit new ecological niches, and ...
... today presented more evidence that it's time for long-time ... when it comes to the treatment of strep throat. ... strep germ, the bug that causes millions of sore ... the job and aren't as effective as newer antibiotics ...
Cached Biology News:Gene increases risk of tuberculosis 2Islands in the Genome Promote Speciation 2Penicillin, amoxicillin: Step aside for strep throat treatment 2Penicillin, amoxicillin: Step aside for strep throat treatment 3
Whole blood is collected from canines (any breed, either sex), refrigerated within 6 hours, processed within 24 hours and frozen at -20C....
... cloning of BAC (100+kb), fosmid (40kb), and ... stability than any othe BAC vector. On ... yields and easy recombinant DNA purification. Available ... (pSMART VC) vectors for the highest insert ...
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure grade propidium iodide is greater than or equal to 98% pure by HPLC....
MOUSE ANTI GUINEA PIG T-CELLS (PAN):FITC Immunogen: Guinea pig peritoneal T-cells...
Biology Products: